Clinical Trial Update: A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa [Phase 2]

View source ↗

Summary

Phase 2 study of nab-sirolimus (ABI-009) in advanced malignant PEComa has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pecoma

Drugs mentioned

• nab-sirolimus (sirolimus (nanoparticle albumin-bound formulation))

Snippet

Sponsor: Aadi Bioscience, Inc. | Conditions: Malignant PEComa | Phase 2 | Status: COMPLETED | Results posted: 2023-04-07